Leading BioPharmaceutical Company AstraZeneca Announces Continued Investment in Maryland and Montgomery County
November 24, 2025
Montgomery County, MD – Last week, global biopharmaceutical company AstraZeneca announced a $2 billion investment in the state of Maryland, including the expansion of its operations in Montgomery County, MD by constructing of a new state-of-the-art clinical manufacturing facility in Gaithersburg. The new facility, which is expected to be operational by 2029, will create 100 good-paying new jobs, retain 400 jobs from other locations in the county, and support 1,000 construction-related jobs. The state is supporting the expansion with an approximately 10% investment match of total project costs.
AstraZeneca has long held a presence in Montgomery County, and recently opened a new, $300 million cell therapy manufacturing facility in Rockville. The 84,000-square-foot building, located at 9950 Medical Center Drive, produces CAR-T cell therapies, which personalizes cancer treatments for patients. This facility alone is expected to create more than 150 skilled jobs in the region, in addition to the 4,500 employees the company employees in Montgomery County across several sites, including its 1.3 million-square campus in Gaithersburg.
The addition of 100 new jobs in the new facility will primarily serve to support AZ’s Research & Development (R&D) activities, supporting the creation of new pharmaceutical drugs not yet approved by the FDA. Additionally, the retention of 400 jobs and relocation of this workforce from other locations will also support R & D.
“AstraZeneca’s choice to deepen its footprint in Montgomery County is a powerful testimony to the strength of our highly educated and diverse workforce, the depth of our innovation ecosystem, and the quality of life that continues to attract and retain world-class companies,” said Montgomery County Executive Marc Elrich. “AstraZeneca represents the kind of partner we value: a multinational leader that understands the importance of talent, innovation, and community. We are proud of its workforce here in the County—proud of the scientists, researchers, engineers, and professionals whose work changes patients’ lives across the world. We are grateful to Governor Moore for his leadership and partnership with AstraZeneca’s to achieve this two billion dollar investment in our state.”
“We are thrilled that AstraZeneca has once again chosen to expand in Montgomery County and in the state of Maryland,” said Elana Fine, Montgomery County Economic Development Corporation’s Board Chair. “The company’s continued investment underscores the unparalleled life sciences ecosystem we’ve built here in Montgomery County. With cutting-edge therapies being researched and developed right here, this expansion further cements our unique position to support global organizations like AstraZeneca. We look forward to deepening our partnership and continuing to support their groundbreaking work.”
The news of the investment not only demonstrates Montgomery County’s business ecosystem and resilience but also helps to further solidify the County as the anchor of the 3rd largest biopharma center in the country.
###